Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 17/20 | 0.53 |
| ▸ | CNR2 | P34972 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5809542 | 0.95 | CNR1 (0.52) | CNR1CNR2 | |
| SCHEMBL5806751 | 0.91 | CNR1 (0.47) | CNR1CNR2 | |
| SCHEMBL5809524 | 0.91 | CNR1 (0.45) | CNR1CNR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5806835 | 0.89 | CNR1 (0.48) | CNR1CNR2 | |
| SCHEMBL6334574 | 0.88 | CNR1 (0.53) | CNR1CNR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5811715 | 0.88 | CNR1 (0.47) | CNR1CNR2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6332750 | 0.87 | CNR1 (0.49) | CNR1CNR2 | |
| SCHEMBL5809967 | 0.85 | CCKAR (0.48) | CNR1CNR2 | |
| SCHEMBL6333137 | 0.83 | CNR1 (0.57) | CNR1CNR2 | |
| SCHEMBL6343581 | 0.83 | CNR1 (0.57) | CNR1CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006060190-A2 | IMIDAZOLE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | WO | claimed |
| WO-2006060199-A2 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF SEXUAL DYSFUNCTION | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | WO | claimed |
| WO-2006060202-A2 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | WO | claimed |
| US-20040063691-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-04-01 | — | — | US | claimed |
| WO-2006060190-A2 | IMIDAZOLE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063691-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | CNR1 405/4885CNR2 340/4885ALDH1A1 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.